& Lindeke, A
2.4 Outcome measures of safety Our study evaluated the safety of tirzepatide with regard to two major adverse events: pancreatic adverse events and the composite of gallbladder or biliary diseases, cholecystitis, cholelithiasis, and biliary diseases
Biermann says
However, several clinical situations, including insulin-resistant states, PCOS, gestational diabetes, and advanced maternal age, have been associated with reduced tissue myo-inositol concentrations or increased urinary loss, as documented in multiple studies between 2019 and 2024
A Western diet (WD) reduces SCFA levels, potentially impairing neuroprotection, insulin signalling, and intestinal barrier function, and promoting endotoxin-producing bacterial translocation, leading to inflammation and reduced insulin sensitivity [106]
Biosimilar development is the medium-term democratization opportunity Biocon Biologics, Samsung Bioepis, and other biosimilar developers are advancing semaglutide biosimilar programs that, upon patent expiry, could reduce drug costs by 70-85% and dramatically expand patient access in both developed markets with coverage barriers and developing markets with affordability constraints
